C5VP001A
Cellicon® Filter Assembly with Durapore® Membrane
filtration area 0.01 m2
Synonym(s):
Cellicon® Perfusion Filter with Durapore® Membrane
About This Item
Recommended Products
material
PET support
PVDF
polyester support
Quality Level
Agency
meets USP Biological Reactivity Test for class VI plastics (family component materials)
sterility
sterile; γ-irradiated (level of 25-40kGy)
flow rate measuring range
10 L/min (/m2)
parameter
1 psi max. reverse press. exposure at 25 °C
1-2.5 L process volume
15 psi at 25 °C (max. burst pressure)
5 psi max. inlet pressure at 25 °C
filtration area
0.01 m2
membrane filtration area
0.01 m2
pore size
5 μm pore size
storage temp.
15-25°C
Looking for similar products? Visit Product Comparison Guide
General description
Application
Seed Train Perfusion
Features and Benefits
Other Notes
Legal Information
consumable
equipment
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
This page describes the design attributes of the Cellicon® filter assembly for cell retention and how they simplify scale-up of intensified upstream processes.
This page describes the financial and operational advantages offered by the Cellicon® Cell Retention Device in an N-1 perfusion process at the 2,000 L scale in comparison to a cell retention device from another supplier.
How the Cellicon® filter and controller enables seamless adoption of a perfused N-1 seed train step into the cell expansion process.
Before adoption of single-use technologies in biomanufacturing, manufacturers must assess the risk to the drug product from potential leachables. This article highlights a general approach based on the United States Pharmacopeia (USP).
Related Content
Enhance perfused seed train efficiency with our cell retention solution. Real-time monitoring and control.
Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.
Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.
Learn more on mAB bioreactor production, and the products you need for this step.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service